B-Type Natriuretic Peptide Predicts Responses to Indomethacin in Premature Neonates with Patent Ductus Arteriosus
- 1 July 2010
- journal article
- research article
- Published by Elsevier in The Journal of Pediatrics
- Vol. 157 (1), 79-84
- https://doi.org/10.1016/j.jpeds.2009.12.045
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- B-type natriuretic peptide levels predict outcome after neonatal cardiac surgeryThe Journal of Thoracic and Cardiovascular Surgery, 2007
- In vivo Dilatation of the Postnatal Ductus Arteriosus by Atrial Natriuretic Peptide in the RatNeonatology, 2007
- The Use of a Bedside Assay for Plasma B-type Natriuretic Peptide as a Biomarker in the Management of Patent Ductus Arteriosus in Premature NeonatesThe Journal of Pediatrics, 2005
- Prostaglandin E 2 —Mediated Relaxation of the Ductus ArteriosusCirculation, 2004
- Indomethacin responsiveness of patent ductus arteriosus and renal abnormalities in preterm infants treated with indomethacinThe Journal of Pediatrics, 2003
- Increased Risk of Necrotizing Enterocolitis in Premature Infants with Patent Ductus Arteriosus Treated with IndomethacinAnnals of Surgery, 1996
- Changing trends in the epidemiology and pathogenesis of neonatal chronic lung diseaseThe Journal of Pediatrics, 1995
- Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus—a double-blind controlled studyThe Journal of Pediatrics, 1981
- Closure of the patent ductus arteriosus with ligation and indomethacin: A consecutive experienceThe Journal of Pediatrics, 1978
- Medical management of small preterm infants with symptomatic patient ductus arteriosusThe Journal of Pediatrics, 1978